Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447569 | 1.00 | FABP5 (0.49) | FABP5FABP7ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL119436 | 1.00 | FABP5 (0.49) | FABP5FABP7ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL30063787 | 1.00 | FABP5 (0.49) | FABP5FABP7ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL29540385 | 1.00 | FABP5 (0.49) | FABP5FABP7ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1847817 | 1.00 | FABP5 (0.49) | FABP5FABP7ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL29447611 | 1.00 | FABP5 (0.49) | FABP5FABP7ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL29549607 | 0.92 | ALDH1A1 (0.58) | FABP5FABP7ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL29503800 | 0.92 | ALDH1A1 (0.58) | FABP5FABP7ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL29503770 | 0.92 | ALDH1A1 (0.58) | FABP5FABP7ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL119560 | 0.92 | ALDH1A1 (0.58) | FABP5FABP7ALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-3727462-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLERD LTD (GB) | 2025-11-05 | — | — | EP | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-14 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-3727461-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-4582436-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BicycleTX Limited (GB) | 2025-07-09 | — | — | EP | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-6528503-B2 | Anticoagulants | MERCK & CO., INC. | 2003-03-04 | — | — | US | disclosed |
| US-20030013700-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2003-01-16 | — | — | US | disclosed |
| EP-0502926-B1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES | RHONE POULENC RORER INT (US) | 1996-03-13 | — | — | EP | disclosed |
| US-5328900-A | Anti-thrombotic peptide and pseudopeptide derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-07-12 | — | — | US | disclosed |
| EP-0502926-A1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES. | RHONE POULENC RORER INT (US) | 1992-09-16 | — | — | EP | disclosed |
| EP-0502926-A4 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES. | RHONE POULENC RORER INTERNAT H (US) | 1992-07-13 | — | — | EP | disclosed |
| US-5064814-A | Anti-thrombotic peptide and pseudopeptide derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-11-12 | — | — | US | disclosed |
| US-5053392-A | Anticoagulants | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-01 | — | — | US | disclosed |
| WO-1991007976-A1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | FABP5 1093/4885FABP7 2453/4885ALDH1A1 2138/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | FABP5 4631/4885FABP7 4721/4885ALDH1A1 4331/4885 |
| US-20030013700-A1 | Thrombin inhibitors | TFPI, PLAT, TFPI2 | FABP5 2498/4885FABP7 4324/4885ALDH1A1 2961/4885 |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | DNPEP, VIP, NPEPPS | FABP5 3048/4885FABP7 2102/4885ALDH1A1 4328/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | FABP5 4631/4885FABP7 4721/4885ALDH1A1 4331/4885 |
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | NGLY1, NPPA, VIP | FABP5 3043/4885FABP7 2774/4885ALDH1A1 4672/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | FABP5 4094/4885FABP7 4602/4885ALDH1A1 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.